what the heck is this kind of name? 'Henri Marie Jean André de Laborde de Monpezat' and how do you fit it in a standard online form?

this is art

Congenital heart disease (CHD) in the spotlight Additional Ventures-New Report: Disproportionate Economic Burden of cCHD: mailchi.mp/b722e3701c16/s… A much needed assessment of the CHD treatment costs on patient families Benoit Bruneau Tony Firulli Mingtao Zhao PhD @ NCH/OSU James R. Priest MD

Rediscovered The Waterboys’ This is the Sea. Such amazing songwriting and musicianship.

Woo hoo! Delighted to see Sally Lowell @[email protected] - fantastic scientist, The Company of Biologists director, champion of sustainability and all round lovely person - win the British Society for Developmental Biology Wolpert Medal 👏👏👏 #BSDBGenSoc2024

Before the movie was this absolute gem of tongue-in-cheek schlock youtube.com/watch?v=ZyhrYi…

Pancreatic cancer is on the rise globally. Early diagnosis has been associated with better outcomes.

In a new article, Anirban Maitra & Eric Topol explore the potential for AI support to help advance detection & care in pancreatic cancer: hubs.li/Q02sFNCp0

This is probably my favourite photo of my kids (many years ago). Captures so much of their essence.

This is Hari. He never has to ask what time a party is. Because they all start when he walks in. 13/10 (IG: hari_1121)

I’m sure that’s not their intent…

Out in nature concurrent with #AACR24
Two papers on biochemistry and preclinical characterization of Revolution Medicines’ RAS(ON) multiRAS inhibitor, with a focus on #PancreaticCancer
KenOliveLab Ben Stanger Der Lab at UNC
nature.com/articles/s4158…
nature.com/articles/s4158…

Autogene cevumeran, a therapeutic mRNA vaccine for pancreatic cancer, continued to show benefit in a three-year follow-up, according to Vinod Balachandran, MD. #AACR24 Vinod BalachandranMD Memorial Sloan Kettering Cancer Center bit.ly/3TRUZdV

Investigation by the amazing Vinod BalachandranMD! These results blow me away and tell me that there is hope at last for pancreatic cancer! Phase 2 trial will be key. Good luck!

This is really big news!

Follow-up Ph1 data for mRNA-based individualized cancer vaccine candidate autogene cevumeran (BNT122) show: 6 of 8 patients with an immune response to the investigational treatment remained tumor-free up to 3 years post treatment. #AACR24 #cancerresearch #oncology

Well good morning

Cardiac researcher takes her work from ‘bench to bedside to Wall Street’: check out this feature on our own Farah Sheikh

today.ucsd.edu/story/medical-…